Finzati - Logo
LNTH logo

Lantheus Holdings, Inc.

LNTH • Drug Manufacturers - Specialty & Generic
$100.97
▼ -0.01 (-0.01%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$6.82B
Growth
1.0%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 15.2%Positive revenue growth · 38.0%Positive free cash flow · 5.25Consistent free cash flow · 5/5Reasonable earnings multiple · 19.23
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 12:39 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$100.97
Change-0.01%
Shares Out67.52M
Market Cap$6.82B
Enterprise Value$6.80B
52W Range49.67 - 111.86
Beta-0.06
P/E24.76
P/S4.38
P/B5.20
P/FCF13.52
EV/Sales4.37

Investment DNA

How strong this company looks for long-term investors

88
out of 100
Business Quality
Margins, moat, returns
83/100
Financial Strength
Debt, cash, stability
92/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
76/100
Why this score▼
Stable or improving margins · 15.2%Positive revenue growth · 38.0%Positive free cash flow · 5.25Consistent free cash flow · 5/5Reasonable earnings multiple · 19.23Manageable debt level · 0.57

Analyst view

Analyst sentiment and price target

LNTH
Analyst sentiment
Based on 19 analyst votes · 2026-09-05
79/100
Bullish
Bullish
11
Hold
8
Bearish
0
Price Target
2026-08-07
Low
$94.00
Mean
$105.25
Median
$102.50
High
$120.00

Company Overview

IPO: 6/25/2015
Industry: Drug Manufacturers - Specialty & Generic
P/B i: 5.20
Debt / Equity i: 0.57
Operating Margin: 20.16%
Net Margin: 15.15%
ROE i: -
ROIC: -

Financial Health

Score18 / 20
Debt / Equity: 0.57
Current Ratio: 2.70
Quick Ratio: 2.51
Status: Strong

Insider Transactions

Recent executive and insider activity

EASTLAND JULIA MARIE
Transaction: 05/14/2026
BUY
Change
+4,137
Price
Not reported
Filing
05/18/2026
Type
BUY
Thrall James H
Transaction: 05/14/2026
BUY
Change
+4,137
Price
Not reported
Filing
05/18/2026
Type
BUY
Ber Gerard
Transaction: 05/14/2026
BUY
Change
+4,137
Price
Not reported
Filing
05/18/2026
Type
BUY